Drug Discovery World

FEBRUARY 20, 2024

One example is that the model can circumvent the difficulties in demonstrating in vivo drug efficacy which arise because of mouse specific metabolism issues. Edinburgh-based PhaSER Biomedical (PhaSER) has received a Bill & Melinda Gates Foundation grant totalling $2.3m A key stage of compound progression.

Drugs 52

Drugs In-Vivo Hormones Development 52

Drug Discovery World

SEPTEMBER 29, 2023

Immunotherapy has taken centre stage this week, with several announcements relating to regulatory approval, investment and research results for antibody and CAR-T therapies, perhaps most significantly, encouraging early-stage data for the first in vivo CAR-T therapy. The top stories: €27.3M

In-Vivo 52

In-Vivo Drugs Antibody Clinical Trials 52

Pharmaceutical Technology

SEPTEMBER 14, 2022

The company is currently progressing its lead drug candidate, RYZ101, into clinical trials for various solid tumour indications. A Phase Ib clinical trial of the drug is underway, enrolling subjects with neuroendocrine tumours, and Phase III trials are anticipated to commence next year.

In-Vivo 130

In-Vivo Clinical Trials Clinical Trials Engineer 130

Drug Discovery World

JULY 5, 2023

Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. RA: What is the current state of the cancer research industry? Mark Garner, PhD., MG: I am responsible for Agilent’s cancer segment.

Research 98

Research Protein Scientist Immune Response 98

pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). billion in potential milestones if the project advances through development and onto the market. billion agreement that started in 2020.

Gene Editing 92

Gene Editing In-Vivo Gene Sequencing Gene 92

Roots Analysis

FEBRUARY 27, 2024

The biopharmaceutical pipeline includes close to 500 gene therapies , several of which are being developed based on CRISPR technology. Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated. The global genome editing market is anticipated to grow at a CAGR of 12.6%

Genome 40

Genome Genomics Gene Gene Editing 40

Drug Discovery World

APRIL 15, 2024

Melissa Little, CEO of the Novo Nordisk Foundation Centre for Stem Cell Medicine “In the stem cell space, 2023 has seen significant increases in the delivery of pluripotent stem cell-derived cell types into first-in-human clinical trials. In addition, I believe we will see more exosome-based therapies enter the clinic in 2024.

Gene Editing 59

Gene Editing Clinical Trials Clinical Trials In-Vivo 59

Drug Discovery World

APRIL 8, 2024

The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Drug Discovery World

JUNE 30, 2023

Research tools, safety testing and regenerative medicines – these endless stem cell applications are powering precision, speed, and new modalities in drug development. Stem cells for use in drug discovery Stem cells are fast becoming an invaluable tool in the drug discovery process. This article is sponsored by Charles River.

Development 52

Development Drugs In-Vitro Gene Therapy 52

Drug Discovery World

JANUARY 18, 2024

Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS). million cases of cancer by 2030 1,2.

In-Vivo 65

In-Vivo Antibody Clinical Trials Clinical Trials 65

Drug Discovery World

FEBRUARY 14, 2024

AlphaMedix is a targeted alpha therapy currently in Phase II clinical development, which consists of an SSTR-targeting peptide complex radiolabeled with lead-212 (212Pb) that serves as an in vivo generator of alpha particles. In the Phase I study, treatment was well-tolerated, with a response rate of 62.5%

In-Vivo 52

In-Vivo FDA Approval Clinical Trials Clinical Trials 52

Drug Discovery World

APRIL 5, 2023

Italian research institute and contract research organisation IRBM has become the only company from outside the United States to join cancer drug discovery network the Chemical Biology Consortium (CBC). The post Only non-US company joins cancer drug discovery consortium appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs In-Vivo In-Vitro Engineer 52

pharmaphorum

OCTOBER 6, 2022

So, when a new disease emerges, researchers have a near-impossible task working upstream from symptoms to identify the underlying cause and biological mechanisms causing disease. This problem is compounded when researchers are presented with a complex set of symptoms, with no easily identifiable infectious agent as the cause.

In-Vivo 98

In-Vivo Research Genetics Drugs 98

XTalks

APRIL 24, 2023

Melanie Blank, clinical team leader for General Medicine Branch 1 at the US Food and Drug Administration’s (FDA) Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT), the agency is seeing one or two new applications coming in every week for new gene therapies for different diseases.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

pharmaphorum

JANUARY 29, 2021

California-based Sangamo Therapeutics is one such company that believes in the powerful potential of in vivo genome editing and regulation, together known as genome engineering, and has built up a sizable preclinical pipeline of genome regulation treatments for diseases such as Huntington’s disease and Amyotrophic lateral sclerosis (ALS).

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

The Pharma Data

MAY 3, 2021

In its 2020 annual report, the division of the US Food and Drug Administration (FDA) tasked with addressing emerging regulatory issues and developing new tools and approaches for regulatory reviews said it was able to expand its efforts despite the COVID-19 pandemic impacting most of the year. . Posted 03 May 2021 | By Michael Mezher .

In-Vitro 52

In-Vitro Clinical Trials Clinical Trials In-Vivo 52

pharmaphorum

FEBRUARY 19, 2021

US biotech Excision BioTherapeutics has raised $60 million to test a potential HIV cure in the clinic, which would use CRISPR technology to snip out the viral code from human cells and tissues. The cash will also help develop two other preclinical drugs, EBT-104 for Herpes Simplex Virus and EBT-107 for hepatitis B.

Gene Editing 105

Gene Editing In-Vivo DNA In-Vitro 105

pharmaphorum

FEBRUARY 13, 2022

German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

Drug Discovery World

AUGUST 22, 2023

Originator pharma companies are developing ever more complex products, which are transforming the medical landscape, but their cost places an increasing burden on healthcare budgets worldwide. It could also include specialty products that are harder to develop compared to standard generic products. What are complex generics?

Production 52

Production Bioequivalency In-Vivo In-Vitro 52

Drug Discovery World

JANUARY 23, 2023

Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care. In addition, they discovered that cladribine, a clinical drug, activates DGKB and inhibits DGAT1. GBM is a WHO grade IV brain tumour with dismal prognosis.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

Camargo

APRIL 28, 2021

Conducting a clinical study in a pediatric patient population requires careful planning, as providing a benefit to a child without causing harm is a weighty responsibility. First Steps Toward Initiating Pediatric Clinical Studies. Data Collection from Preclinical and Adult Studies. Non-Linear Mixed Effect Modeling (NLMEM).

Clinical Trials 130

Clinical Trials Clinical Trials In-Vivo Drugs 130

FDA Law Blog

FEBRUARY 2, 2023

Since 1962, the FD&C Act has authorized FDA to require that sponsors of clinical trials submit data from “preclinical tests (including tests on animals)” in order to demonstrate that their drug is safe enough to advance to testing in humans. For more on FDORA’s other provisions, see HPM’s complete summary here ). 42 U.S.C. §

Clinical Trials 64

Clinical Trials Clinical Trials In-Vivo In-Vitro 64

Drug Discovery World

AUGUST 14, 2023

Over the past few decades, the incredible progress in personalised medicine has led to the development of life-saving cell and gene therapies (CGT). For instance, in a trial where patients are selected based on a specific human leukocyte antigen (HLA) type, the FDA requires the use of a fully certified, FDA approved Companion Diagnostic.

Gene Therapy 52

Gene Therapy Marketing Gene DNA 52

Drug Discovery World

JULY 3, 2023

From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

Drug Discovery World

JUNE 14, 2023

In subsequent articles, themes cover future regulatory changes and redefining manufacturing. Although the panel didn’t have enough time to discuss automated systems for culturing of MSC, automated systems such as our company’s Quantum Flex provides an option to developers. First, the importance of cell collections.

In-Vivo 52

In-Vivo Gene Manufacturing Development 52

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

JUNE 17, 2022

Researchers from the Institut Pasteur, Université Paris Cité, and INSERM examined 102 SARS-CoV-2 spike monoclonal antibodies cloned from the B cells of 10 COVID-19 convalescents. The research has its roots in a task force launched by the Institut Pasteur in the early days of the COVID-19 pandemic.

Antibody 52

Antibody In-Vivo In-Vitro Immune Response 52

The Pharma Data

APRIL 8, 2022

The mere motions of breathing are known to influence vital functions of the lungs, including their development in babies, the production of air-exchange-enhancing fluid on their inner surfaces, and maintenance of healthy tissue structure. a Wyss Technology Development Fellow at the Institute.

Immune Response 52

Immune Response In-Vivo Genetic Analysis Research 52

Drug Discovery World

FEBRUARY 6, 2023

WM : Infinimmune is an early-stage antibody biotechnology company, focused on reinventing antibody drug discovery by developing human-derived antibody drugs. However, the limited number of drugs and targets demonstrates the need for new approaches to both discovery and development. This has consequences for safety and efficacy.

Antibody 52

Antibody Immune Response Genome Genomics 52

Drug Discovery World

NOVEMBER 16, 2022

DDW Editor Reece Armstrong learns about Molecular Devices’ Organoid Innovation Centre (OIC) and how the company is aiming to advance research into 3D biology and organoids. . 2D biology has been used by pharmaceutical researchers for decades. 2D vs 3D .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

XTalks

FEBRUARY 10, 2023

According to a recent review published in Nature , as of April 2022 almost 1,800 active cell therapy clinical trials were listed in ClinicalTrials.gov, a 33 percent increase from 2021. In a recent webinar, Dr. Vassallo discussed the operational considerations for complex cell therapy clinical trials.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Gene Therapy 52

Drug Discovery World

OCTOBER 20, 2022

This technology has resulted in the launch of a proprietary pipeline of several drug discovery projects, which now range from in vitro to in vivo phases, especially in oncology and immuno-oncology. . Through this investment, we are thrilled to be part of this exciting journey and further expand Bpifrance portfolio in deeptech and AI.” .

Drugs 52

Drugs In-Vivo In-Vitro Engineer 52

Drug Discovery World

JULY 22, 2022

As a result, researchers are striving to continually improve immuno-oncology approaches using the patient’s own immune cells to combat tumours. After approval of many well-known ICIs, including Keytruda and nivolumab (Opdivo), there was a push to show therapeutic efficacy pre-clinically in mice.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

pharmaphorum

JANUARY 25, 2022

To demonstrate how quickly the digital therapeutics space is developing, it is easiest to state that the first such therapy was approved in 2018 and since that point the annual investment in the space has more than doubled in the intervening years. Developing a digital therapy. This equated to $21.3 This equated to $21.3

Medicine 111

Medicine In-Vivo In-Vitro Development 111

Delveinsight

FEBRUARY 11, 2021

Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes. . However, they have only shrunk tumors in about half of patients who took them, along with chemotherapy, in the clinical trials.

Gene Therapy 52

Gene Therapy Gene Immune Response In-Vivo 52

Drug Discovery World

DECEMBER 14, 2023

We are advancing our clinical evaluation of MBRC-101 in breast cancer, as well as for patients with other EphA5-expressing solid tumour cancers for whom there is a significant need for targeted treatment options.” Vepdegestrant is the only PROTAC ER degrader in late-stage clinical development.

HR 52

HR Hormones Trials In-Vivo 52

XTalks

APRIL 22, 2022

Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. What is Flow Cytometry?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98